ClinicalTrials.gg

Program

relacorilant

Also written as “Relacorilant”, “CORT125134” and “Relacorilant 150 mg”.

Its studies are mostly in Cushing Syndrome · Ovarian Neoplasms · Carcinoma, Pancreatic Ductal · Adrenocortical Carcinoma · Pancreatic Neoplasms, led by Corcept Therapeutics.

Furthest: phase 3, since Sep 27, 201822 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Corcept Therapeutics223 open or runningphase 3since Sep 27, 2018Apr 11, 2016Dec 2026phase 2 · NCT03604198

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Apr 11, 2016.

  1. Mar 1, 2018Phase 1 study in HealthyNCT03457597 · 27 enrolled · United States
  2. Apr 3, 2018Phase 1 study in HealthyNCT03512548 · 52 enrolled · United States
  3. May 1, 2018Phase 2 study in Cushing SyndromeNCT03604198 · 125 enrolled · United States, Austria, Canada and more
  4. May 17, 2018Phase 1 study in HealthyNCT03540836 · 30 enrolled · United States
  5. Sep 27, 2018Phase 3 study in Cushing SyndromeNCT03697109 · 152 enrolled · United States, Austria, Bulgaria and more
  6. Dec 13, 2018Phase 2 study in Ovarian NeoplasmsNCT03776812 · 178 enrolled · United States, Belgium, Canada and more
  7. Feb 27, 2020Phase 3 study in Cushing SyndromeNCT04308590 · 137 enrolled · United States, Austria, Bulgaria and more
  8. Mar 13, 2020Phase 3 study in Pancreatic NeoplasmsNCT04329949 · 43 enrolled · United States
  9. Apr 30, 2020Phase 1 study in Adrenocortical CarcinomaNCT04373265 · 15 enrolled · United States
  10. Jan 29, 2021Phase 1 study in HealthyNCT04795479 · 36 enrolled · United States
  11. Feb 4, 2022Phase 3 study in Ovarian NeoplasmsNCT05257408 · 381 enrolled · United States, Argentina, Australia and more
  12. Apr 18, 2022Phase 1 study in Cushing SyndromeNCT05347979 · 30 enrolled · United States
  13. Oct 17, 20234 phase 1 studiesNCT06094790, NCT06094738, NCT06094725 and 1 more
  14. Nov 3, 2025Phase 2 study in AdenocarcinomaNCT07259317 · 80 planned · United States

Ahead

  1. Dec 2026Primary completion: phase 2 study in Cushing SyndromeNCT03604198
  2. Sep 2027Primary completion: phase 2 study in AdenocarcinomaNCT07259317

TargetBeta

NR3C1 →read by rule
“Glucocorticoid receptor antagonist”ChEMBL 37, by rule

Other programs on NR3C1

ProgramCompanyFurthest phaseStudies
DexamethasoneruleAbbViephase 4174
BudesonideruleAstraZenecaphase 4167
fluticasone furoateruleGlaxoSmithKlinephase 497
PrednisoneruleJohnson & Johnsonphase 465
BeclomethasoneruleChiesi Farmaceuticiphase 446
PrednisoloneruleSanofiphase 434
betamethasone dipropionateruleLEO Pharmaphase 427
MethylprednisolonerulePfizerphase 423
dexamethasone phosphateruleeyegate-pharmaceuticals-incphase 421
vamorolonerulereveragen-biopharma-incphase 411
BetamethasoneruleLEO Pharmaphase 49
Triamcinoloneruleresearch-insight-llcphase 45

Studies

All 22 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07259317Adenocarcinoma · United States2RecruitingSep 202780
NCT06094790Healthy · United States1CompletedNov 15, 201732
NCT06094738Healthy · United States1CompletedNov 16, 202030
NCT06094725Hepatic Impairment · United States1CompletedDec 14, 202030
NCT06094712Healthy · United States1CompletedApr 27, 20168
NCT05347979Cushing Syndrome · United States1CompletedJul 19, 202230
NCT05257408Ovarian Neoplasms · United States, Argentina, Australia and more3Active, not recruitingMar 31, 2025381
NCT04795479Healthy · United States1CompletedMay 17, 202136
NCT04373265Adrenocortical Carcinoma · United States1CompletedOct 17, 202315
NCT04329949Pancreatic Neoplasms · United States3TerminatedAug 23, 202143
NCT04308590Cushing Syndrome · United States, Austria, Bulgaria and more3CompletedSep 19, 2024137
NCT03776812Ovarian Neoplasms · United States, Belgium, Canada and more2CompletedMar 16, 2021178
NCT03697109Cushing Syndrome · United States, Austria, Bulgaria and more3CompletedApr 8, 2024152
NCT03540836Healthy · United States1CompletedJul 16, 201830
NCT03604198Cushing Syndrome · United States, Austria, Canada and more2Active, not recruitingDec 2026125
NCT03512548Healthy · United States1CompletedJul 29, 201952
NCT03457597Healthy · United States1CompletedApr 15, 201827
NCT03442621Healthy · United States1CompletedFeb 28, 201830
NCT03508635Healthy · United Kingdom1CompletedDec 2015130
NCT03067376Healthy · United Kingdom1CompletedSep 20169
NCT02804750Cushing Syndrome · United States, Hungary, Italy and more2CompletedSep 201835
NCT02762981Triple Negative Breast Neoplasms · United States2CompletedMay 12, 202085

How it is read

Names in the registry

  • “Relacorilant”, 9 entries
  • “CORT125134”, 3 entries
  • “relacorilant”, 1 entry
  • “Relacorilant 150 mg”, 1 entry
  • “Relacorilant, 100 mg and 25 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.